Program
lebrikizumab
Also written as “Lebrikizumab”, “lebrikizumab (MILR1444A)” and “LY3650150”.
Its studies are mostly in Dermatitis, Atopic · Asthma · Nasal Polyps · Rhinitis, Allergic, Perennial · Pulmonary Disease, Chronic Obstructive, led by 4 companies.
Drug pageLebrikizumab: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 194 open or running | phase 4since May 28, 2025 | Feb 16, 2018 | May 2027phase 3 · NCT06338995 |
| Hoffmann-La Rocheits history only | 180 open or running | phase 3since May 29, 2013 | Oct 27, 2008 | none ahead |
| Almirallits history only | 63 open or running | phase 3since Nov 26, 2021 | Nov 26, 2021 | Apr 25, 2027phase 3 · NCT06526182 |
| Tanox | 10 open or running | phase 2since May 17, 2006 | May 17, 2006 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Tanox only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 17, 2006First study: phase 2 study in Hodgkin DiseaseFirst studyNCT00441818 · 59 enrolled · United States
TargetBeta
“A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities”NCIt, by rule
“Interleukin-13 inhibitor; Interleukin-13 inhibitor”ChEMBL 37, by rule
Other programs on IL13
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tilrekimig | Pfizer | phase 3 | 11 |
| lunsekimig | Sanofi | phase 3 | 10 |
| zumilokibart | AbbVie | phase 2 | 4 |
| ompekimig | Pfizer | phase 2 | 3 |
| GHZ339 | Novartis | phase 2 | 1 |
| ABBV-313 | AbbVie | phase 1 | 1 |
Studies
The one study Tanox leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00441818Hodgkin Disease · United States | 2 | UNKNOWN | 59 |
How it is read
Names in the registry
- “Lebrikizumab”, 37 entries
- “lebrikizumab”, 7 entries
- “lebrikizumab (MILR1444A)”, 5 entries
- “LY3650150”, 2 entries
- “TNX-650”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 21 studies
- Asthma, 12 studies
- Nasal Polyps, 1 study
- Rhinitis, Allergic, Perennial, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.